Innovation Status of Gene Therapy for Breast Cancer

  • Anaya-Ruiz, Maricruz (Laboratory of Cellular Biology, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social) ;
  • Perez-Santos, Martin (Directorate of Innovation and Knowledge Transfer, Benemerita Universidad Autonoma de Puebla)
  • Published : 2015.05.18


Background: To analyze multi-source data including publications and patents, and try to draw the whole landscape of the research and development community in the field of gene therapy for breast cancer. Materials and Methods: Publications and patents were collected from the Web of science and databases of the five major patent offices of the world, respectively. Bibliometric methodologies and technology are used to investigate publications/patents, their contents and relationships. Results: A total of 2,043 items published and 947 patents from 1994 to 2013 including "gene therapy for breast cancer" were retrieved. The top five countries in global publication share were USA, China, Germany, Japan and England. On the other hand, USA, Australia, England, South Korea and Japan were the main producers of patents. The universities and enterprises of USA had the highest amount of publication and patents. Adenovirus- and retrovirus-based gene therapies and small interfering RNA (siRNA) interference therapies were the main topics both in publications and patents. Conclusions: The above results show that global research in the field of gene therapy for breast cancer is increasing and the main participants in this field are USA and Canada in North America, China, Japan and South Korea in Asia, and England, Germany, and Italy in Europe. Also, this article demonstrates the usefulness of bibliometrics to address key evaluation questions and define future areas of research.


Breast cancer;gene therapy;patents;publications;innovation


  1. Anaya-Ruiz M, Vallejo-Ruiz V, Flores-Mendoza L, Perez-Santos M (2014). Female breast cancer incidence and mortality in Mexico, 2000-2010. Asian Pac J Cancer Prev, 15, 1477-9.
  2. Antunes A, Fierro IM, Di Sabato R, Rohem dos Santos P, Lins Mendes FM (2013). R&D landscape for breast cancer through patent documents. J Cancer Ther, 4, 56.
  3. Dogan N, Toprak D (2014). Female breast cancer mortality rates in Turkey. Asian Pac J Cancer Prev, 15, 7569-7573.
  4. Donato HM, De Oliveira CF (2006). Breast pathology: evaluation of the Portuguese scientific activity based on bibliometric indicators. Acta Medica Portuguesa, 19, 225-34.
  5. Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase No. 11. Lyon, France: international agency for research on cancer. Last accessed October. 2014.
  6. Canongia C (2007). Synergy between competitive intelligence (CI), knowledge management (KM) and technological foresight (TF) as a strategic model of prospecting-the use of biotechnology in the development of drugs against breast cancer. Biotechnology Advances, 25, 57-74.
  7. Ha R, Chow D, Wynn R, (2014). Global trend in breast cancer imaging research 1992-2012: bibliometry study. AJR Am J Roentgenol, 202, 696-7.
  8. Hong W, Dong E (2014). The past, present and future of breast cancer research in China. Cancer Lett, 351, 1-5.
  9. Ibraheem D, Elaissari A, Fessi H (2014). Gene therapy and DNA delivery systems. Int J Pharm, 459, 70-83.
  10. Kotepui M, Wannaiampikul S, Chupeerach C, Duangmano S, (2014). A bibliometric analysis of diets and breast cancer research. Asian Pac J Cancer Prev, 15, 7625-8.
  11. Majeed W, Aslam B, Javed I, et al (2014). Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev, 15, 3353-8.
  12. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E (2014). European cancer mortality predictions for the year 2014. Ann Oncol, 25, 1650-6.
  13. McCrudden CM, McCarthy HO (2014). Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet, 7, 209-220.
  14. Moghimi M, Fathi M, Marashi A, et al (2013). A scientometric analysis of 20 years of research on breast reconstruction surgery: a guide for research design and journal selection. Arch Plast Surg, 40, 109-15.
  15. Perez-Santos JLM, Anaya-Ruiz M (2013). Mexican breast cancer research output, 2003-2012. Asian Pac J Cancer Prev., 14, 5921-23.
  16. Petrocca F, Lieberman J (2014). Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol, 29, 747-54.
  17. Shahkhodabandeh S, Piri Z, Biglo MH, et al (2009). Breast cancer in Iran: iranian scientists approach to breast cancer researchers in medline database. Iranian Quarterly J Breast Disease, 2, 49-59.
  18. Shi XJ, Au WW, Wu KS, Chen LX, Lin K (2014). Mortality characteristics and prediction of female breast cancer in China from 1991 to 2011. Asian Pac J Cancer Prev, 15, 2785-91.
  19. Youlden DR, Cramb SM, Yip CH, Baade PD (2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 11, 101-15.
  20. Walther W, Schlag PM (2014), Current status of gene therapy for cancer. Curr Opin Oncol, 25, 659-64.

Cited by

  1. Suppression of SOX18 by siRNA inhibits cell growth and invasion of breast cancer cells vol.35, pp.6, 2016,
  2. Tracing the knowledge-building dynamics in new stem cell technologies through techno-scientific networks vol.112, pp.3, 2017,